Infrastructure at Scale: A Conversation with Germfree’s New CEO
May 26, 2026
We speak with Carol Houts about advanced therapy manufacturing, modular cleanrooms, and the challenge of scaling GMP infrastructure
7 min read
False
Advertisement
Latest
Cell Therapy Manufacturing: A Medicine Maker’s “Dream”
May 25, 2026
Why CTMC CEO Jason Bock relishes the challenge of solving cell therapy’s most complex manufacturing and delivery problems
13 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
Analytical Champions: Tao Chen
May 22, 2026
A new series championing analytical scientists in pharma begins with Genentech’s rising star
7 min read
Turning Medical Insights into Patient Impact
By Manuel Möller
May 21, 2026
Veeva research reveals a stark gap between the insights biopharma captures and the actions it takes – highlighting a missed opportunity to improve patient outcomes
5 min read
Rethinking Progress in Clinical Trials
May 20, 2026
Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development
9 min read
This Week’s Biopharma News: FDA Commissioner Steps Down
May 19, 2026
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
3 min read
Three Trends Shaping Multi-omics Sample Preparation
By Malin Karlsson
May 19, 2026
Maximizing insight from limited samples, aligning data across molecular layers, and building consistency from the first step
3 min read
Scaling Genomics for Precision Medicine
By Robert Balog
May 18, 2026
How advances in microarray technology are helping bring genomic data closer to real-time clinical decision-making
4 min read
This Week’s CGT News: Novo’s Parkinson’s Pivot
May 18, 2026
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
6 min read
